RT Book, Section
A1 Reichman, Eric F.
SR Print(0)
ID 57703560
T1 Chapter 35. Automatic Implantable Cardioverter-Defibrillator Assessment
T2 Emergency Medicine Procedures, 2e
YR 2013
FD 2013
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-161352-1
LK accessemergencymedicine.mhmedical.com/content.aspx?aid=57703560
RD 2024/04/25
AB The  introduction  of  implantable  cardioverter-defibrillator  (ICD)  technology  has  revolutionized  the  fields  of  cardiology  and  electrophysiology.  More  than  100,000  such  devices  are  implanted  annually  in  the  United  States  alone.  ICDs  allow  life-threatening  ventricular  tachycardia  and  ventricular  fibrillation  to  be  safely  controlled  and  benefit  patients  at  risk  for  sudden  cardiac  death.  Multiple  studies  (e.g.,  CABG  patch,  MADIT,  MADIT  II,  MUSTT,  DINAMIT,  AMIOVIRT,  COMPANION,  SCD-HEFT)  have  examined  the  prophylactic  indication  for  ICD  therapy  in  high-risk  groups.1–7  The  ICD  is  becoming  a  more  common  therapeutic  option  for  the  young  population  with  a  diagnosis  of  Brugada  syndrome,  prolonged  QT  syndrome,  and  hereditary  cardiomyopathies  to  name  a  few.